Aurisco PharmaceuticalLtd Management

Management criteria checks 2/4

Aurisco PharmaceuticalLtd's CEO is Dingjun Chu, appointed in Jun 2017, has a tenure of 6.92 years. directly owns 0.81% of the company’s shares, worth CN¥80.58M. The average tenure of the management team and the board of directors is 6.9 years and 6.9 years respectively.

Key information

Dingjun Chu

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	6.9yrs
CEO ownership	0.8%
Management average tenure	6.9yrs
Board average tenure	6.9yrs

Recent management updates

Recent updates

Here's Why We Think Aurisco PharmaceuticalLtd (SHSE:605116) Might Deserve Your Attention Today

Apr 22

CEO

Dingjun Chu (50 yo)

6.9yrs

Tenure

Mr. Dingjun Chu is General Manager and Director of Aurisco Pharmaceutical Co.,Ltd. since June 01, 2017.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Dingjun Chu	GM & Director	6.9yrs	no data	0.81% CN¥ 80.6m
Liqin Zhang	Deputy GM & Director of Sales	6.9yrs	no data	0.044% CN¥ 4.4m
Guoping Wang	Deputy GM & Director	6.9yrs	no data	no data
Fangfang Li	Board Secretary	6.9yrs	no data	no data
Zhenping Zhao	Deputy General Manager	6.2yrs	no data	0.062% CN¥ 6.1m

6.9yrs

Average Tenure

50yo

Average Age

Experienced Management: 605116's management team is seasoned and experienced (6.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Dingjun Chu	GM & Director	6.9yrs	no data	0.81% CN¥ 80.6m
Guoping Wang	Deputy GM & Director	4yrs	no data	no data
Feng Zhen Liu	Independent Director	6.9yrs	no data	no data
Yizhou Chu	Vice Chairman	6.9yrs	no data	31.71% CN¥ 3.1b
Zhien Peng	Chairman of the Board	6.9yrs	no data	37.81% CN¥ 3.7b
Jianwen Li	Director	6.9yrs	no data	1.72% CN¥ 170.5m
Peijing Qiu	Director	6.9yrs	no data	2.75% CN¥ 272.9m
Ping Jin	Chairman of the Supervisory Board	6.9yrs	no data	0.81% CN¥ 80.6m
Hua Pan	Independent Director	6.9yrs	no data	no data
Yue Zhou	Supervisor	6.9yrs	no data	no data

6.9yrs

Average Tenure

57yo

Average Age

Experienced Board: 605116's board of directors are considered experienced (6.9 years average tenure).

Aurisco PharmaceuticalLtd Management

Management criteria checks 2/4

Key information

Recent management updates

Aurisco Pharmaceutical Co.,Ltd., Annual General Meeting, May 20, 2024

No independent directors

No independent directors

Recent updates

Aurisco Pharmaceutical Co.,Ltd., Annual General Meeting, May 20, 2024

Here's Why We Think Aurisco PharmaceuticalLtd (SHSE:605116) Might Deserve Your Attention Today

Aurisco Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 29, 2024

Investor sentiment deteriorates as stock falls 17%

Aurisco Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.17 in 3Q 2022)

Investor sentiment improves as stock rises 20%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.19 in 2Q 2022)

Aurisco Pharmaceutical Gets Auxiton(R) (Dydrogesterone) as First Generic Approval in China

Aurisco Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

No independent directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.13 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No independent directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.10 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.42 (vs CN¥0.52 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: CN¥13.10

Investor sentiment deteriorated over the past week

New 90-day low: CN¥15.71

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

New 90-day low: CN¥16.38

Third quarter earnings released

Market bids up stock over the past week

Aurisco Pharmaceutical Co.,Ltd. has completed an IPO in the amount of CNY 343.17 million.

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age